Navigation Links
AMDL, Inc. Announces Strategic Realignment
Date:10/14/2008

Company restructures business into three distinct divisions that include in

vitro diagnostics, cancer therapeutics and China-based integrated

pharmaceuticals

TUSTIN, Calif., Oct. 14 /PRNewswire-FirstCall/ -- (http://www.amdl.com) AMDL, Inc. (Amex: ADL), a vertically integrated pharmaceutical company with major operations in China and the US, today announced it has restructured its business into three distinct divisions to better reflect the Company's operational focus on becoming a world-class, diversified pharmaceutical company.

The new divisions include an In Vitro Diagnostics (IVD) division specifically focused on accelerating AMDL's market launch for the AMDL-ELISA DR-70(R) (FDP) cancer test; a Cancer Therapeutics division specifically focused on accelerating research for its Combination Immunogene Therapy (CIT) technology; and a China-based Integrated Pharmaceuticals division focused on the continued manufacturing, sales and distribution of AMDL's broad range of generic, specialty and branded pharmaceutical products.

AMDL will continue to execute its 2008 business plan with a focus on achieving its stated financial target of a 100% increase in sales over 2007. Additionally, under this new operational structure, AMDL will aggressively work to:

-- Establish the IVD division for DR-70 with a structural platform for

funding the division through a potential joint-venture partnership(s)

or selling the division as a stand-alone business;

-- Establish the Cancer Therapeutics division with a structural platform

for funding the division through a potential joint-venture

partnership(s) or selling the division as a stand-alone business;

-- Continue accelerating the manufacturing, sales & marketing of AMDL's

diverse China-based pharmaceutical product portfolio through the

Integrated Pharmaceuticals division; and,

-- Leverage AMDL's current assets and resources to drive future growth.

"Segmenting AMDL's operations into these three distinct divisions provides us with greater market focus, increased flexibility across our diverse product portfolio, and a solid platform to successfully execute AMDL's key business goals," commented Mr. Gary Dreher, President and CEO of AMDL. "We've achieved significant growth in sales and gross profits over the past 18 months and believe this refinement will strengthen AMDL's long-term growth position as a leading developer, manufacturer and supplier of high-quality diagnostic and pharmaceutical products."

For additional information on AMDL and its diversified product portfolio visit the Company's website at http://www.amdl.com or contact AMDL Investor Relations at 206.310.5323.

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated bio-pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs approximately 320 people in the U.S. and China. The Company has an additional 4 pharmaceutical and diagnostic products under review by various regulatory authorities.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties related to the Company's access to additional capital, competition and dependence on key management.

Kristine Szarkowitz

Director-Investor Relations

kszarkowitz@amdl.com

(Tel :) 206.310.5323


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008
2. AMDL, Inc. Closes Private Placement of Convertible Notes
3. The Wall Street Transcript Interviews AMDL, Inc. CEO & President Gary Dreher for Fall Healthcare Issue
4. Rudd Report Highlights AMDL, Inc.s Latest Business Achievements; Supports 2008 Financial Guidance
5. AMDL, Inc. Retains Strategic Growth International Inc. as its Global Investor Relations Advisor
6. Sysmex Announces Clinical Laboratory Software Name Change
7. Mirixa Announces Agreement With the Pharmacy Guild of Australia
8. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
9. BioNanomatrix Announces Appointment of Dr. Pui-Yan Kwok to Its Scientific Advisory Board
10. WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance
11. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased ... of over 5.5 million people each year. Especially those living in larger cities are ... - based in one of the most pollution-affected countries globally - decided to take ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and ... rebranding initiative announced today. The bold new look is part of a transformation ... moves into a significant growth period. , It will also expand its service offering ...
(Date:10/10/2017)... ... , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on August ... MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... and business process optimization firm for the life sciences and healthcare industries, announces ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):